D&O insurance and director liability at listing

Why director liability changes at the moment of listing

A private company's directors face claims from employees, competitors, customers and occasionally regulators. Listing adds a constituency with both the incentive and the means to sue: public shareholders who bought on the strength of a document the directors signed. That exposure does not begin on listing day — it begins with the prospectus and the roadshow.

In the US, the Securities Act of 1933 imposes a demanding standard on directors and officers for material misstatements or omissions in a registration statement (https://www.sec.gov/about/laws.shtml); a claim of that kind does not require proof of intent, which is why US securities litigation concentrates in the first years after a listing. In the EU, the Prospectus Regulation (EU) 2017/1129 sets the disclosure standard and leaves civil liability for the prospectus to national law (https://eur-lex.europa.eu/eli/reg/2017/1129/oj); the UK applies the same structure through the FCA's Prospectus Regulation Rules (https://www.handbook.fca.org.uk/handbook/PRR/). Australia's Corporations Act 2001 (https://www.legislation.gov.au/C2004A00818/latest) and Hong Kong's prospectus regime (https://www.elegislation.gov.hk/) do comparable work in their markets.

Two consequences shape the planning. First, liability attaches to individuals by name, not only to the company — so the insurance policy, the indemnity and the constitutional documents have to be read as one package. Second, the claim window opens during drafting, so a policy bound the week after listing has already left the board exposed for the riskiest stretch of the process.

What the policy has to cover

Public-company D&O programmes are normally built on three insuring agreements sharing one tower of limits:

What changes at IPO is not the labels but the scope. Private-company forms typically grant broad entity cover across employment, regulatory and commercial claims; the public-company form narrows entity cover to securities claims. If the pre-IPO policy stays in place unchanged, the board loses cover precisely where it is needed most.

Prospectus liability must be expressly granted, either by endorsement to the D&O or through a separate prospectus liability policy running alongside it. Ask the broker to confirm in writing that wrongful acts committed during drafting, verification, the roadshow and the offer itself are within scope, and whether the insurer treats the prospectus as a single claim or a claim per investor.

A standalone Side A layer — often written on a difference-in-conditions basis with its own limit — is worth considering whenever the company could become insolvent, because it responds to non-indemnifiable loss even when the underlying insurers decline. It is the layer that keeps a director's personal assets out of play.

Finally, map the ancillary lines: employment practices, fiduciary, cyber and crime. They are separate policies on separate limits, and a claim that could sit in two places is a claim that two insurers will each try to push elsewhere.

Run-off for selling shareholders and exiting directors

When shares are sold and new directors join, part of the board leaves. Those individuals need cover for wrongful acts committed before they went, and the company's go-forward policy will generally not respond to them.

Two run-off questions usually arise. First, the existing private-company policy may contain a change-in-risk clause or a change-of-control trigger that converts it to run-off automatically once the offer crosses a defined ownership threshold — and the insurer is often under no obligation to offer an extended reporting period unless one is requested in writing. Second, the selling shareholders and retiring directors may need a dedicated run-off policy with its own limits, bought while the placement is still competitive.

Treat the run-off as a deliverable of the IPO project, not an afterthought: it has an owner, a date and a premium line in the IPO cost budget. Set the run-off period by reference to the limitation periods that apply to the relevant claims in the listing jurisdiction, and record why that duration was chosen.

Timing the placement against the prospectus

Placement is a critical-path item that sits behind counsel and the reporting accountants but ahead of the roadshow. A workable sequence:

• Appoint the insurance broker and risk adviser at the same time as the legal advisers, not later.
• Prepare the underwriting submission from the draft prospectus, the latest audited financial information and the risk-factor section. Insurers will not price a programme against a blank.
• Run a competitive tender with insurer meetings before the roadshow has a fixed date.
• Bind before the roadshow starts.
• Decide the architecture: a dedicated IPO/prospectus liability policy running concurrently with the new public-company D&O, or an endorsement extending a single programme. Where the existing private policy carries a prospectus exclusion, a concurrent policy is usually cleaner.
• Align inception dates so there is neither a gap nor duplicate cover across the private and public towers.

Give yourself more runway than feels necessary. Late placement means fewer insurers quoting, an uncompetitive price and terms dictated by whoever will still look at the file.

Exclusions and gaps to test

Read the draft policy line by line and challenge these:

• Prospectus or offering exclusion, whether full or partial.
• Change-in-risk and transaction clauses that switch the policy to run-off at listing.
• Prior known circumstances and pending litigation wording — a known claim or circumstance must be disclosed at renewal or it may never be covered.
• Insured-versus-insured exclusions and how they interact with derivative claims.
• Fraud, dishonesty and personal-profit exclusions, and whether they apply only after a final adjudication.
• Entity cover limited to securities claims, which is the standard public-company position.
• Defence-cost erosion of limits if the tower is shared across Side A, B and C.
• Warranty statements about knowledge of prior circumstances, which can be used to unwind the lower layers after the event.
• Sanctions and local-admitted-policy requirements in any international programme.

Where cover narrows, the fix is usually a specific endorsement with its own limit rather than a broader whole-policy promise — that is where negotiating effort pays.

Indemnification agreements, minutes and the paper trail

Insurance is the backstop; indemnification is the primary mechanism. Before the policy is bound, the company secretary or general counsel should:

• Review the constitutional documents and any shareholder agreement for indemnity and advancement rights, and adapt them to the listing jurisdiction.
• Put individual indemnification agreements in place for each director and officer, consistent with the charter. An agreement may add detail and procedure, but it cannot undercut rights given at constitutional level.
• Settle the carve-outs: claims a director brings on their own account, control of defence, choice of counsel and recovery of fees incurred enforcing indemnity rights.
• Confirm that local company law permits the indemnity, and that the company can fund defence costs as they arise rather than only after a final outcome.
• Minute the decisions: approval of the programme with its limits and retention, approval of the indemnity agreements, and a review of cover against the prospectus timetable. Where a selling shareholder's nominee sits on the board, record how that conflict was handled.
• File the chain — policies, slips, endorsements, indemnity agreements and the minutes — in the data room. Buyers, underwriters and regulators all ask for it.
• Disclose the arrangements where the prospectus rules require it, including any indemnity the company gives to the underwriters.

How the structure and approach differ by listing route

On US exchanges, the combination of strict prospectus liability and an active securities class-action market produces the highest limits and the highest pricing. Programmes are typically layered ABC towers with securities-only entity cover, a differential Side A layer and a competitive broker-led tender. Because the exposure window opens with the registration statement and the roadshow, binding before the roadshow is not a preference but a requirement in practice.

In the UK and Europe, prospectus liability sits with the issuer, the offeror and the persons responsible for the prospectus under the applicable prospectus rules, but the enforcement ecosystem differs from the US and collective redress mechanisms are still developing. Programmes are smaller, more likely to be placed with a local admitted policy plus a master layer, and the private-to-public transition is driven by the change-in-risk wording rather than by a single rule. Continental European issuers often need local admitted paper for their home market and for their operating companies.

In Asia-Pacific practice is deliberately fragmented: Australia applies its own prospectus and continuous disclosure regime alongside the ASX listing rules, Hong Kong relies on its companies and securities legislation, and Singapore and Japan each have their own disclosure regimes. Local admitted policies matter more, capacity is thinner, and multi-layer programmes with fronting arrangements are common — so start the placement earlier than you would in London.

For any cross-border listing, the test is consistency: every layer should use compatible definitions of claim, wrongful act and loss, or the programme will argue with itself at the worst possible moment.

Getting it right: owners and evidence

The workstream belongs jointly to the CFO and the company secretary, with the broker, listing counsel and corporate counsel as the delivery team. The board approves, the project office tracks it on the IPO timeline, and the evidence lands in the data room. Book the run-off placement into the IPO cost budget, keep the underwriting submission moving in step with the prospectus, and treat the indemnity agreements and minutes as part of the same deliverable — because in the event of a claim, they will all be tested together.